UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~April~~June 1826, 2023 (~~April~~June 1423, 2023)

FUSE MEDICAL, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware	000-10093	59-1224913
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

1565 North Central Expressway Suite 220 Richardson, Texas		75080
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (469) 862-3030

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		FZMD		OTCPink

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 25.0207 Submission ~~Results~~ of ~~Operations~~Matter ~~and~~to ~~Financial~~a ~~Condition.~~Vote of Security Holders

~~The~~On ~~information~~June in23, ~~Item~~2023, 2Fuse Medical, Inc.02 of(the ~~this~~“Company”) ~~report~~held ~~(including~~its ~~Exhibit~~2023 ~~99.1)~~Annual ~~shall~~Meeting ~~not~~of beStockholders ~~deemed~~(the “~~filed~~Annual Meeting”). ~~for~~The ~~purposes~~total number of ~~Section~~shares 18 of ~~the~~common ~~Securities~~stock ~~Exchange~~eligible ~~Act~~to ofvote ~~1934,~~ as ~~amended~~of (the ~~“Exchange~~record ~~Act”)~~date, orApril ~~otherwise~~25, ~~subject~~2023, was 73,895,794 and, pursuant to the ~~liabilities~~Company’s ofBylaws, ~~that section~~36,947,898 shares ~~nor~~were ~~shall~~required itto be ~~deemed~~present ~~incorporated~~or byrepresented ~~reference~~at inthe ~~any~~Annual ~~filing~~Meeting ~~under~~to ~~the~~constitute ~~Securities~~a ~~Act~~quorum. ofThe ~~1933,~~total asnumber ~~amended,~~of orshares ~~the~~of ~~Exchange~~common ~~Act,~~stock ~~except~~present asor ~~expressly~~represented ~~provided~~at bythe ~~specific~~Annual ~~reference~~Meeting inwas ~~such~~64,521,761, and a ~~filing.~~quorum therefore existed.

OnAt ~~April 18, 2023, Fuse Medical, Inc. (~~the ~~“Company”)~~Annual issued a press release reporting the financial results of the Company for the year ended December 31, 2022. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.Meeting:

~~Item 9~~1.01 ~~Financial~~Election ~~Statements~~of ~~and~~Board ~~Exhibits~~of Directors. The following persons were elected as directors of the Company for a one-year term expiring at the 2024 Annual Meeting of Stockholders with the following vote:

(d) Exhibits.

Name	Votes For	Votes Against	Votes Withheld	Broker Non-Votes
Renato V. Bosita, Jr., MD	63,087,944	61,351	2	1,372,464
Mark W. Brooks	63,132,848	16,447	2	1,372,464
Lawrence S. Yellin	63,091,848	57,447	2	1,372,464
Christopher C. Reeg	63,132,854	16,441	2	1,372,464

Exhibit Number		Description
99.1*		Press Release, dated April 18, 2023
104		Cover page Interactive Data File (embedded within the inline XBRL document)

2.	Ratification of the Selection of M&K CPAS, PLLC (M&K). The selection of M&K to act as an independent registered public accounting firm for the Company for the fiscal year ending December 31, 2023 was ratified by a vote of (i) 64,474,346 in favor, (ii) 47,224 against, and (iii) 191 abstaining.

* Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Company Name
	Fuse Medical, Inc.
Date: April 18, 2023	By:	/s/ Lawrence S. Yellin
Date: June 26, 2023	By:	/s/ Christopher C. Reeg
		Lawrence S. Yellin
		Christopher C. Reeg,
		Chief Financial Officer and Director
		Chief Executive Officer and Director

Filing Compare · Fuse Medical, Inc.